Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 305,741 Shares

Posted by George Bondi on May 13th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 305,741 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $0.70, for a total transaction of $214,018.70. Following the sale, the director directly owned 1,273,008 shares of the company’s stock, valued at approximately $891,105.60. This trade represents a 19.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $43,446.40.
On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $22,745.16.
On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $49,824.18.
On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.66, for a total transaction of $9,659.10.
On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $4,733.40.
On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total value of $34,533.36.
On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $42,627.62.
On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total value of $121,148.64.
On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $39,025.71.
On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $69,650.76.

Werewolf Therapeutics Stock Down 4.3%

Shares of HOWL opened at $0.63 on Wednesday. Werewolf Therapeutics, Inc. has a 12-month low of $0.53 and a 12-month high of $2.38. The business’s fifty day moving average is $0.81 and its 200 day moving average is $0.83. The stock has a market cap of $30.72 million, a P/E ratio of -0.51 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. On average, analysts expect that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently made changes to their positions in the business. Regal Investment Advisors LLC raised its stake in shares of Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the period. Vontobel Holding Ltd. raised its stake in shares of Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares during the period. Qube Research & Technologies Ltd bought a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $48,000. AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics during the 1st quarter worth $79,000. Finally, Bridgeway Capital Management LLC increased its holdings in Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HOWL has been the topic of a number of recent research reports. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Werewolf Therapeutics has a consensus rating of “Hold” and a consensus target price of $3.75.

View Our Latest Stock Analysis on HOWL

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.